About

Our editorial approach

We compile and summarize public sources with an emphasis on safety, screening, and oversight uncertainty. Our processes prioritize primary registries, peer-reviewed literature, and official guidance when available, and we flag areas where direct evidence is sparse.

How content is sourced

Contributors survey clinical registries and academic databases, cross-check claims against peer-reviewed papers, and consult official guidance such as national health authorities or recognized standards bodies when they exist. For example, we reference broad clinical-safety frameworks similar to those described by institutions like the U.S. National Library of Medicine on MedlinePlus (MedlinePlus) when discussing screening and cardiac risks in general clinical care.

We also place findings in context using established overviews; where appropriate we reference comprehensive primers such as a high-level encyclopedia entry on the topic's pharmacology (ibogaine — Wikipedia) to distinguish historical facts from clinical claims.

Mission & audience

Mission: Cautious Lantern is an independent resource on ibogaine treatment in Costa Rica, focused on evidence, safety risks, screening, and oversight uncertainty. Our audience includes people researching treatment options and families seeking clear, sober context about potential benefits and major risks.

Editorial principles

• Safety before claims. Prioritize information that helps readers assess risk.
• Evidence over hype. Cite primary sources and note study limitations.
• Plain language. Explain technical concepts clearly for non-specialists.
• Transparent uncertainty. Label what is not known.

We structure our material so readers can quickly locate a risk brief, review the sourcing, and follow links to primary literature or official sources when they want to verify details. For example, when we describe screening considerations we reference established clinical practice frameworks and registry summaries similar to resources maintained by academic centers (PubMed / NCBI).

Who this is for

This site is intended for people researching ibogaine-related care and their families who need clear context about safety and oversight. We do not provide medical advice; our summaries are informational and designed to support conversations with qualified clinicians.

How we vet information

Our vetting emphasizes triangulation: independent registry entries, peer-reviewed studies, and official statements from health authorities where available. Where formal guidance is absent we flag uncertainty and document the basis for any interpretive statements. If you land here from another page, note that you can return to our main resource hub via the site's front page; for broader topic navigation follow the editorial pathways from the homepage at the top of the site.

Operationally, we prefer sources that are openly accessible or archived; when citing regulatory context we look to government health pages or academic institutions rather than unverified promotional materials. For general principles about evidence grading and clinical recommendations, recognized references such as major university reviews provide helpful context (Harvard University serves as an example of institutional health commentary) — we use such sources to explain methodology, not to endorse specific treatments.

If you are exploring services, our services overview describes how we classify listings and what caveats we apply when describing provider claims.